Biomarin Pharmaceutical Inc. BM8

XET: BM8 | ISIN: US09061G1013   24/11/2023
81,02 EUR (-0,12%)
(-0,12%)   24/11/2023

8 mei 2024 · BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV · Persbericht

4 mei 2024 · New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting · Persbericht

24 april 2024 · BioMarin Reports Record Financial Results for the First Quarter 2024 · Persbericht

10 april 2024 · BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET · Persbericht

12 maart 2024 · New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting · Persbericht

7 maart 2024 · BioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer · Persbericht

1 maart 2024 · BioMarin Scheduled to Participate in March Investor Conferences · Persbericht

22 februari 2024 · BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024 · Persbericht

8 februari 2024 · BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET · Persbericht

6 februari 2024 · BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress · Persbericht

3 januari 2024 · BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA · Persbericht

20 december 2023 · BioMarin Announces Governance Enhancements and Value Creation Initiatives · Persbericht

1 november 2023 · BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year · Persbericht

1 november 2023 · BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer · Persbericht

20 oktober 2023 · U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia · Persbericht

17 oktober 2023 · BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET · Persbericht

21 september 2023 · BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting · Persbericht

15 september 2023 · BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia · Persbericht

11 september 2023 · BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York · Persbericht

6 september 2023 · BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th · Persbericht

Mijn selecties